Real-world comparative effectiveness of atezolizumab versus durvalumab for extensive-stage small-cell lung cancer - PubMed
3 hours ago
- #Small-cell lung cancer
- #Atezolizumab
- #Durvalumab
- Atezolizumab (AEP) and durvalumab (DEP) combined with platinum-etoposide are standard first-line treatments for extensive-stage small-cell lung cancer (ES-SCLC).
- A multicenter retrospective study of 234 patients showed similar progression-free survival (PFS) and overall survival (OS) between AEP and DEP.
- Safety profiles were comparable between the two treatment groups.
- Economic analysis revealed nearly identical quality-adjusted life years (QALYs) but lower total direct medical costs for AEP.
- Patients with platinum-sensitive relapse had significantly longer OS than those with platinum-refractory relapse after second-line chemotherapy.
- AEP may be the more cost-minimizing option due to its lower cost with comparable efficacy and safety.